BioSpace News Archive

Alto Neuroscience Announces CEO Amit Etkin, M.D., Ph.D., Named as an Entrepreneur Of The Year ® 2023 Bay Area Award Finalist.

Novaliq Announces Presentation of New Scientific Data on CyclASol ® 0.1% (Cyclosporine Ophthalmic Solution) at the American Society of Cataract and Refractive Surgery Annual Meeting.

CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week ® Conference.

Spesana has announced the formation of the Spesana Advisory Board with appointments of experienced industry leaders across clinical sites, life science companies and diagnostic labs.

Tris Pharma, Inc. today announced the appointments of Thomas Englese as chief commercial officer and Marc Lesnick, Ph.D., as chief development officer.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).

Bryn Pharma, LLC announced today the addition of three new executives to its leadership team: Nurry Hong, Chief Strategy and Business Development Officer; Steve Killmeyer, Chief Financial Officer (CFO); and, Lisa Lucifero, VP, Head of Human Resources. Michael Kaseta, CFO of Liquidia Corporation (Nasdaq: LQKA), has also been appointed to Bryn’s Board of Directors.

Berkeley SkyDeck, the global hub for entrepreneurship and a leading accelerator, today announced that it has welcomed the first three companies for its new SkyDeck LSEC Bio Track: AsparaGlue, Editpep, and MZR Neurotech

NeuroSense Therapeutics Ltd. today announced positive preliminary results from a novel biomarker study conducted to evaluate the potential of NeuroSense’s combination platform therapy for the treatment of Parkinson’s disease (PD), the second most common neurodegenerative disorder.

Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers, using proprietary ferroptosis with immuno-oncology targeted novel biologics, today announced that its Founder and CEO Randy Milby will be presenting at the following industry and financial investor conferences.